Patients with expected survival <12 months are excluded; Can it be explained the way this condition is determined? subjective criterion of the physician who attends the patient? If the patient does not need contacts with the project nurses or the MePACs because everything goes well for a long time, is there any type of periodic contact established? If so, it would be interesting to explain.
One objective, which I consider very important due to the type of intervention, is to evaluate the COST BENEFIT of the study. However, it is not described in the analysis, nor detailed how it will be considered and treated.
In acknowledgments, mention is made to some persons who are authors (Dr Jamie Layland)?
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GENERAL COMMENTS
This is a protocol for a trial of telemonitoring in heart failure with a primary outcome of the level of compliance with recommended daily weighing compared to a non-telemonitoring control group. The protocol is generally clear and complies with CONSORT standards. However, there are a few issues which need consideration before publication. Summary: The use of Bluetooth scales in telemonitoring has been reported before so this should probably not be described as novel Trial Design: It would appear that the project nurses recruit the patients, do the assessments and provide the intervention. This makes it an open trial and it should be described as such rather than leaving the reader to work it out for themselves. This aspect of the trial should also be considered in the discussion Primary and secondary outcomes: I didn't really understand the sentence starting ' the rate of time ...' . Please could you consider rewording it. Also, the outcome measures in Table 2 The study will provide important information on management and simple telemonitoring control in heart failure. The protocol is well structured and adequate to properly develop the study.
Some RECOMMENDATIONS, in order to further improve the article are:
Comment: Try to include MESH TERMS as keywords. "chronic heart failure" can be replaced by "heart failure", and "telemonitoring" by "telemedicine" or "telehealth".
Response: We have substituted "heart failure" for "chronic heart failure", and substituted "telehealth" for "telemonitoring" (Key words, line 15, page 2) Comment: The FIRST STRENGH mentioned of the study ("first RCT that...") should be specified better, since in the introduction it is said that 4 clinical trials with similar objectives have been found although of little duration or including few patients.
Response: We thank you for the comment. We agree that "the first" might be too strong. Accordingly we have removed "the first" with the following two changes: 1. We have substituted "A multicentre randomized controlled trial…" for "The first multicentre randomized controlled trial…" in the section of "Strength and limitations of this study" (Line 20, page 2). 2.
Substituted "This trial will examine the patient compliance…" for "This trial will be the first to examine the patient compliance…" in the last paragraph, Introduction (Line 54, page 3) Comment: It would be interesting that the authors explained in the article something more in detail the DETERMINATION AND RECRUITMENT OF ELIGIBLE PATIENTS. This is explained in detail in the protocol, but not so much in the article.
Response: I have accordingly added the information on the sources for screening, and added the statement given below: "Through the trial, project nurses at the trial sites will use their electronic patient administration systems to screen patients with CHF from medical records of patient presentations at the local hospitals and emergency departments. They will also screen patient records at heart failure outpatient clinics, and community healthcare services. The nurses will then record eligible candidates, and accordingly send an invitation letter to the candidates." (Line 33-39, page 4) Comment: Patients with expected survival <12 months are excluded; Can it be explained the way this condition is determined? subjective criterion of the physician who attends the patient?
Response: To clarify this, I have added "such as patients with documented palliative care in medical records", the section of "Inclusion and exclusion criteria" (Line 9, page 5) Comment: If the patient does not need contacts with the project nurses or the MePACs because everything goes well for a long time, is there any type of periodic contact established? If so, it would be interesting to explain.
Response: If the patient does not need contacts with the project nurses or the MePACs based on the alert system, there is not any periodic contact between the nurse and patient. The objective of the program is to improve the patient adherence/compliance.
We did not make any change in the paper for this comment. Comment: One objective, which I consider very important due to the type of intervention, is to evaluate the COST BENEFIT of the study. However, it is not described in the analysis, nor detailed how it will be considered and treated.
Response: The "cost benefits" in the paper were mainly about reducing hospital readmissions, and improving other outcomes given in "Health Economic Outcomes". We understand that it was confusing to add a new concept of "cost benefits" in the paper.
To address this, we have removed "cost benefits" from the paper, Primary and secondary outcomes (Line 49, page 6). Additionally, we also substituted "health economic outcomes" for "economic outcomes" to make this category name consistent with that given in Table 2 
Reviewer 2
Reviewer Name: Janet Hanley Institution and Country: Edinburgh Napier University, UK Please state any competing interests: None declared Please leave your comments for the authors below This is a protocol for a trial of telemonitoring in heart failure with a primary outcome of the level of compliance with recommended daily weighing compared to a non-telemonitoring control group. The protocol is generally clear and complies with CONSORT standards. However, there are a few issues which need consideration before publication.
Comment:
Summary: The use of Bluetooth scales in telemonitoring has been reported before so this should probably not be described as novel Response: We thank you for the comment. We understand that use of Bluetooth scales is not novel. Our intention was to highlight the strength of using a large multicentre trial to evaluate the patient compliance. We guess "the first" was misleading in the paper. Accordingly, we have removed "the first" with the following two changes: 1.
We have substituted "A multicentre randomized controlled trial…" for "The first multicentre randomized controlled trial…" in the section of "Strength and limitations of this study" (Line 20, page 2).
2.
Substituted "This trial will examine the patient compliance…" for "This trial will be the first to examine the patient compliance…" in Introduction (Line 54, page 3)
